Yi Young-Su
Department of Biological Sciences, Kyonggi University, Suwon 16227, Republic of Korea.
Int Immunopharmacol. 2025 Jun 5;157:114787. doi: 10.1016/j.intimp.2025.114787. Epub 2025 May 3.
Inflammation is a body's immune defense against infection and injury. The inflammatory response has two main phases: the priming and triggering phases. The triggering phase involves the activation of inflammasomes, cytoplasmic platforms for initiating inflammation, and Inflammasomes are classified into two categories: canonical and noncanonical. Kidney disease, or renal disease, refers to damage or illness affecting the kidneys, leading to a progressive decline in their function. Although the roles of canonical inflammasomes in kidney diseases are well-documented, recent research highlights novel roles of noncanonical inflammasomes in managing various inflammatory conditions. In particular, emerging studies emphasize the regulatory functions of noncanonical inflammasomes in a range of kidney diseases. This review explores recent discoveries regarding the regulatory functions of noncanonical inflammasomes, including human caspase-4/5 and murine caspase-11, in the progression of kidney diseases. It also examines the potential of targeting these inflammasomes as a novel therapeutic approach.
炎症是机体对感染和损伤的免疫防御反应。炎症反应主要有两个阶段：启动阶段和触发阶段。触发阶段涉及炎性小体的激活，炎性小体是启动炎症的细胞质平台，并且炎性小体分为两类：典型炎性小体和非典型炎性小体。肾脏疾病是指影响肾脏的损伤或疾病，会导致其功能逐渐下降。虽然典型炎性小体在肾脏疾病中的作用已有充分记载，但最近的研究突出了非典型炎性小体在管理各种炎症状态中的新作用。特别是，新出现的研究强调了非典型炎性小体在一系列肾脏疾病中的调节功能。本综述探讨了关于非典型炎性小体（包括人类半胱天冬酶-4/5和小鼠半胱天冬酶-11）在肾脏疾病进展中的调节功能的最新发现。它还研究了将这些炎性小体作为一种新型治疗方法的潜力。
